Drug firm research has lower impact

October 2012
GP: General Practitioner;10/3/2012, p16
The article reports on the study which suggests that doctors are less likely to act on the findings of research funded by pharmaceutical companies in the U.S. It indicates that doctors were 37% less likely to consider prescribing a drug on the basis of studies from pharmaceutical companies. The researchers argue that the respondents downgraded the credibility of industry-funded trials.


Related Articles

  • Expectations vs. Reality. Stern, Philip; Ehrenberg, Andrew // Marketing Research;Spring2003, Vol. 15 Issue 1, p40 

    Focuses on the stages of evidence on how doctors prescribe. Way to increase the sales of drugs according to a survey of European pharmaceutical marketing managers; Differences in the way drugs are prescribed.

  • Americans make risky healthcare trade-offs to save money.  // PharmacoEconomics & Outcomes News;10/29/2011, Issue 640, p2 

    The article suggests that doctors consider the financial interests of their patients after respondents in a poll conducted by the U.S. Consumer Reports Health Ratings Center expressed their misgivings about the influence of the pharmaceutical industry on the prescribing practices of their doctors.

  • Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Clinical Investigator Prescribing Behavior? Harold E. Glass // Disease Management;Mar2004, Vol. 7 Issue 1, p77 

    The advancement of science requires the cooperation of clinical investigators. Recent discourse, which attempts to relate pharmaceutical company grant payments to clinical investigators to subsequent preferential prescribing behavior, erodes the physician/patient relationship and may lead to an...

  • Clinical Trial Investigators and Their Prescribing Patterns. Psaty, Bruce M.; Rennie, Drummond // JAMA: Journal of the American Medical Association;6/21/2006, Vol. 295 Issue 23, p2787 

    The editorial focuses on drug industry-sponsored clinical trials and the prescribing patterns of physicians. Observational research in Denmark by Andersen and colleagues found that doctors participating in research for an asthma drug showed preference for the company's product. The design of a...

  • Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. Spurling, Geoffrey K.; Mansfield, Peter R.; Montgomery, Brett D.; Lexchin, Joel; Doust, Jenny; Othman, Noordin; Vitry, Agnes I. // PLoS Medicine;Oct2010, Vol. 7 Issue 10, p1 

    Background: Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing,...

  • Rx for Big Pharma: Pharmacists are Job 1. Plagakis, Jim // Drug Topics;Oct2012, Vol. 156 Issue 10, p66 

    In this article the author comments on the exclusion of pharmacists by pharmaceutical companies for their brand promotion in the U.S. According to the author, though the doctors write the prescription, but pharmacists play an important role in promoting drugs to the patients. Also, he discusses...

  • AN ACE IN THE WHOLE. Howie, Patrick; Luby, Mike // Medical Marketing & Media;Aug2009, Vol. 44 Issue 8, p56 

    The article offers information on the challenges encountered by the pharmaceutical companies in the U.S. Eventhough companies succeeded in launching and marketing their products, they encountered problems with regards to physicians because some of them did not follow prescription guidelines set...

  • Following the Script: How Drug Reps Make Friends and Influence Doctors. Fugh-Berman, Adriane; Ahari, Shahram // PLoS Medicine;Apr2007, Vol. 4 Issue 4, pe150 

    This article, which grew out of conversations between a former drug rep and a physician who researches pharmaceutical marketing, reveals the strategies used by reps to manipulate physician prescribing.

  • GPs have 'unhealthy' relationship with reps.  // Pulse;6/2/2003, Vol. 63 Issue 22, p4 

    Reports on the criticism of journal 'BMJ' on the relationship between pharmaceutical industry and general practitioners on drug prescription consequences for patients in Great Britain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics